GLP1R and early-onset autosomal dominant Alzheimer disease: The robust data gained from animal studies has prompted the examination of GLP-1 receptor agonists in clinical trials of Alzheimer’s disease (Gerstein et al., 2019; Cukierman-Yaffe et al., 2020) and Parkinson’s disease (Aviles-Olmos et al., 2013, 2014) with promising results.